| Literature DB >> 32033944 |
Liming Liu1,2, Jianrong Wu3,4, Guoxing Zhu5,2, Nannan Yin5,2, Qiuling Luo5,2, Jia Liu5,2, Xiulai Chen5,2.
Abstract
To enhance the growth performance of Saccharomyces cerevisiae under osmotic stress, mutant XCG001, which tolerates up to 1.5 M NaCl, was isolated through adaptive laboratory evolution (ALE). Comparisons of the transcriptome data of mutant XCG001 and the wild-type strain identified ELO2 as being associated with osmotic tolerance. In the ELO2 overexpression strain (XCG010), the contents of inositol phosphorylceramide (IPC; t18:0/26:0), mannosylinositol phosphorylceramide [MIPC; t18:0/22:0(2OH)], MIPC (d18:0/22:0), MIPC (d20:0/24:0), mannosyldiinositol phosphorylceramide [M(IP)2C; d20:0/26:0], M(IP)2C [t18:0/26:0(2OH)], and M(IP)2C [d20:0/26:0(2OH)] increased by 88.3 times, 167 times, 63.3 times, 23.9 times, 27.9 times, 114 times, and 208 times at 1.0 M NaCl, respectively, compared with the corresponding values of the control strain XCG002. As a result, the membrane integrity, cell growth, and cell survival rate of strain XCG010 increased by 24.4% ± 1.0%, 21.9% ± 1.5%, and 22.1% ± 1.1% at 1.0 M NaCl, respectively, compared with the corresponding values of the control strain XCG002 (wild-type strain with a control plasmid). These findings provided a novel strategy for engineering complex sphingolipids to enhance osmotic tolerance.IMPORTANCE This study demonstrated a novel strategy for the manipulation of membrane complex sphingolipids to enhance S. cerevisiae tolerance to osmotic stress. Elo2, a sphingolipid acyl chain elongase, was related to osmotic tolerance through transcriptome analysis of the wild-type strain and an osmosis-tolerant strain generated from ALE. Overexpression of ELO2 increased the content of complex sphingolipid with longer acyl chain; thus, membrane integrity and osmotic tolerance improved.Entities:
Keywords: adaptive laboratory evolution; complex sphingolipid; membrane engineering; membrane integrity; osmotic tolerance
Year: 2020 PMID: 32033944 PMCID: PMC7117927 DOI: 10.1128/AEM.02911-19
Source DB: PubMed Journal: Appl Environ Microbiol ISSN: 0099-2240 Impact factor: 4.792
FIG 1Global transcriptome analysis of the adaptive laboratory evolution (ALE) mutant XCG001 and the wild-type strain. (A) Cell growth trajectory showing changes in fitness during ALE in YNB medium with different concentrations of NaCl. The concentration of NaCl was stepwise improved from 0.5 to 1.5 M over time (orange line). (B) Maximum specific exponential growth rates of the wild-type strain and mutant XCG001 in YNB medium supplemented with increasing concentrations of salt. The half-maximal inhibitory concentration (IC50) was calculated by using the fitting curve of the data. (C) Growth profiles of mutant XCG001 and the wild-type strain in YNB medium under the 0 M NaCl condition. (D) Growth profiles of mutant XCG001 and the wild-type strain in YNB medium under the 1.5 M NaCl condition. (E) Venn diagrams depicting the numbers of upregulated and downregulated genes in the wild-type strain and mutant XCG001 under the 1.5 M NaCl condition compared with those genes’ expression levels in the corresponding strains under the 0 M NaCl condition. (F) Numbers of upregulated and downregulated genes in mutant XCG001 relative to their expression in the wild-type strain under 0 M and 1.5 M NaCl conditions.
FIG 2Overexpression of ELO2 enhanced osmotic tolerance. (A) Control strains XCG002 (wild-type strain with a control plasmid pY13), P (XCG016), P (XCG017), and P (XCG010) were spotted on YNB plates at 0 M and 1.0 M NaCl. (B) Maximum specific exponential growth rates of strains XCG002, XCG016, XCG017, and XCG010 in YNB supplemented with increasing NaCl concentrations. The half-maximal inhibitory concentration (IC50) was calculated by fitting the curve to the data. (C and D) Growth curves of strains XCG002, XCG016, XCG017, and XCG010 at 0 M and 1.0 M NaCl. (E) The survival rates of strains XCG002, XCG016, XCG017, and XCG010 over a range of NaCl doses (0.00, 0.25, 0.50, 0.75, and 1.00 M). All data are presented as mean values from three independent experiments. Error bars indicate the standard deviations. **, P < 0.01.
FIG 3Overexpression of ELO2 enhanced very long fatty acid content. (A) Fatty acid contents in strains XCG002, XCG016, XCG017, and XCG010 at 0 M NaCl. (B) Fatty acid contents in strains XCG002, XCG016, XCG017, and XCG010 at 1.0 M NaCl. (C) The fatty acid average length of strains XCG002, XCG016, XCG017, and XCG010 at 0 M and 1.0 M NaCl. (D) Unsaturation/saturation ratio of strains XCG002, XCG016, XCG017, and XCG010 at 0 M and 1.0 M NaCl. All data are presented as mean values from three independent experiments. Error bars indicate the standard deviations. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
FIG 4Overexpression of ELO2 changed complex sphingolipid contents. (A to F) Phospholipid content (including phosphatidylserine [PS], phosphatidic acid [PA], phosphatidylinositol [PI], phosphocholine [PC], phosphatidylglycerol [PG], and phosphatidylethanolamine [PE]) changed in strain XCG002 and strain XCG010 at 0 M and 1.0 M NaCl. (G) The ratio of complex sphingolipid (including phosphorylceramide [IPC], mannosylinositol phosphorylceramide [MIPC], mannosyldiinositol phosphorylceramide [M(IP)2C] content in strain XCG010) to that of control strain XCG002 changed at 0 M and 1.0 M NaCl. All data are presented as mean values from three independent experiments. Error bars indicate the standard deviations. *, P < 0.05; **, P < 0.01.
FIG 5Complex sphingolipid improved osmotic tolerance. (A) The mRNA level of the complex sphingolipid biosynthesis genes in strains XCG002 and XCG010 at 0 M NaCl. (B) The mRNA level of complex sphingolipid biosynthesis genes in strains XCG002 and XCG010 at 1.0 M NaCl. (C) The ratio of complex sphingolipid content in strain XCG018 (deletion of LAC1 in strain XCG010) to that of the control strain XCG002 changed at 0 M and 1.0 M NaCl. (D) Strains XCG002, XCG010, and XCG018 were spotted on plates containing or not containing 1.0 M NaCl. (E) The survival rates of strains XCG002, XCG010, and XCG018 over a range of NaCl doses (0.00, 0.25, 0.50, 0.75, and 1.00 M). All data are presented as mean values from three independent experiments. Error bars indicate the standard deviations. *, P < 0.05; **, P < 0.01.
FIG 6Increased complex sphingolipids changed membrane integrity. (A and B) Fluorescent microscopy analysis of membrane integrity in the XCG002, XCG010, and XCG018 cells at 0 M (A) or 1.0 M NaCl (B). Under the view of a confocal fluorescence microscope, all cells showed red fluorescence with an integral membrane, while only cells with a damaged membrane showed green fluorescence. Cells with a damaged membrane can be stained by SYTOX green, and cells with integral or damaged membrane all can be stained by FM4-64. The scale is 25 μm. (C and D) Flow cytometry analysis of membrane integrity in strains XCG002, XCG010, and XCG018 at 0 M or 1.0 M NaCl. All data are presented as mean values from three independent experiments.
Strains used in this study
| Strain | Relevant characteristic | Source |
|---|---|---|
| Strains | ||
| BY4741 | This study | |
| XCG001 | ALE mutant of BY4741 that tolerates 1.5 M NaCl | This study |
| XCG002 | BY4741 harboring pY13 | This study |
| XCG003 | BY4741 harboring pY13-FET4 | This study |
| XCG004 | BY4741 harboring pY13-ADH6 | This study |
| XCG005 | BY4741 harboring pY13-PHO89 | This study |
| XCG006 | BY4741 harboring pY13-EGT2 | This study |
| XCG007 | BY4741 harboring pY13-SAH1 | This study |
| XCG008 | BY4741 harboring pY13-HXT4 | This study |
| XCG009 | BY4741 harboring pY13-SKG6 | This study |
| XCG010 | BY4741 harboring pY13-ELO2 | This study |
| XCG011 | BY4741 harboring pY13-URA1 | This study |
| XCG012 | BY4741 harboring pY13-HXK2 | This study |
| XCG013 | BY4741 harboring pY13-YBL111C | This study |
| XCG014 | BY4741 harboring pY13-RNR1 | This study |
| XCG015 | BY4741 harboring pY13-SRL1 | This study |
| XCG017 | BY4741 harboring pY131-ELO2 | This study |
| XCG017 | BY4741 harboring pY132-ELO2 | This study |
| XCG018 | Gene | This study |
| Plasmids | ||
| pY13 | 2μm, | Laboratory storage |
| pY13-FET4 | 2μm, | This study |
| pY13-ADH6 | 2μm, | This study |
| pY13-PHO89 | 2μm, | This study |
| pY13-EGT2 | 2μm, | This study |
| pY13-SAH1 | 2μm, | This study |
| pY13-HXT4 | 2μm, | This study |
| pY13-SKG6 | 2μm, | This study |
| pY13-ELO2 | 2μm, | This study |
| pY13-URA1 | 2μm, | This study |
| pY13-HXK2 | 2μm, | This study |
| pY13-YBL111C | 2μm, | This study |
| pY13-RNR1 | 2μm, | This study |
| pY13-SRL1 | 2μm, | This study |
| pY131 | Replace pY13 promoter PTEF with promoter PADH1 | This study |
| pY132 | Replace pY13 promoter PTEF with promoter PTDH3 | This study |
| pY131-ELO2 | 2μm, | This study |
| pY132-ELO2 | 2μm, | This study |
Primers used in this study
| Primer function and name | Sequence (5′–3′) |
|---|---|
| Overexpression | |
| FET4-F1 | TAGTGGATCCATGGGTAAAATTGCA |
| FET4-F2 | ATGACTCGAGCTATTTTTCCAACATCATA |
| ADH6-F1 | CTAGTGGATCCATGTCTTATCCTGAGAA |
| ADH6-F2 | ATGACTCGAGCTAGTCTGAAAATTCT |
| PHO89-F1 | TAGTGGATCCATGGCTTTACATCAA |
| PHO89-F2 | ATGACTCGAGTTATGTCATTTGGTATTC |
| EGT2-F1 | GCAGGAATTCATGAATAAACTATTGTTACATCT |
| EGT2-F2 | ATGACTCGAGTTACAGCAGAAATGAGA |
| SAH1-F1 | TAGTGGATCCATGTCTGCTCCAGCT |
| SAH1-F2 | ATGACTCGAGTCAATATCTGTAGTGG |
| HXT4-F1 | TAGTGGATCCATGTCTGAAGAAGCTG |
| HXT4-F2 | ATGACTCGAGCTACTTTTTTCCGAAC |
| SKG6-F1 | TAGTGGATCCATGTACCACACCCATA |
| SKG6-F2 | ATGACTCGAGTCAGTTGACGGTATAATT |
| ELO2-F1 | TAGTGGATCCATGAATTCACTCGTTAC |
| ELO2-F2 | ATGACTCGAGTTACCTTTTTCTTCTGTG |
| URA1-F1 | TAGTGGATCCATGACAGCCAGTTTAACTA |
| URA1-F2 | ATGACTCGAGTTAAATGCTGTTCAACTT |
| HXK2-F1 | TAGTGGATCCATGGTTCATTTAGGTCC |
| HXK2-F2 | ATGACTCGAGTTAAGCACCGATGATAC |
| YBL111C-F1 | TAGTGGATCCATGAAAGTTTCCGATAG |
| YBL111C-F2 | ATGACTCGAGTCAGTGACAAACTCCT |
| RNR1-F1 | TAGTGGATCCATGTACGTTTATAAAAGAGAC |
| RNR1-F2 | ATGACTCGAGTTAACCCGAACACATTTC |
| SRL1-F1 | TAGTGGATCCATGCTTCAATCCGTT |
| SRL1-F2 | ATGACTCGAGTCACCAACTGGTCGAA |
| Replace promoter | |
| PADH1-F1 | GCTGGAGCTCATCCTTTTGTTGTTTCC |
| PADH1-F2 | GGATCCACTAGTTCTAGAAGTTGATTGTATGCTTGG |
| PTDH3-F1 | GCTGGAGCTCTCATTATCAATACTGCCA |
| PTDH3-F2 | CTAGTTCTAGATTTGTTTGTTTATGTGTGTTTATTC |
| Gene deletion | |
| L-lac1-F1 | GAATGAAAAATAGTTGGAAAGGAAACA |
| L-lac1-F2 | AGCTCTTGTTTATTGATACTGTGTC |
| Leu2 (lac1)-F1 | AGTATCAATAAACAAGAGCTATGTCTGCCCCTAAGAAGAT |
| Leu2 (lac1)-F2 | CTTAAAAACACCGTTTTCCTTTAAGCAAGGATTTTCTTAACTTCTTCG |
| R-lac1-F1 | AGGAAAACGGTGTTTTTAAGTAGTA |
| R-lac1-F2 | CATATTTAGTTTGCACTGAAGGAGAA |
| RT-PCR | |
| LAC1-F1 | TTCACTTCTGGTAACACTA |
| LAC1-F2 | CTAATAGCGAACGGTCTA |
| LAG1-F1 | CTTGACTGGTGACTCTAA |
| LAG1-F2 | TATGATATGGCTACGAACA |
| AUR1-F1 | ATGGTCATACACTTCAAT |
| AUR1-F2 | GGTTCATCAGTCATATTAAG |
| CSG2-F1 | CAAGTGTAATAGGCTACG |
| CSG2-F2 | AAGGTCAGATAGAAGGTTA |
| IPT1-F1 | CATCTTCATTCACCGTAT |
| IPT1-F2 | TTATTGCCATTGCTGTTA |